Fertility Preservation in Breast Cancer Patients Under Special Consideration of Ovarian Stimulation for Fertility Purposes

Sebastian Findeklee (1), Sebastian Grewe (2), Klaus Diedrich (3)
(1) Kinderwunschzentrum Niederrhein, Madrider Straße 6; D-41069 Mönchengladbach, Germany AND Department of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Hospital, Kirrberger Straße 100, Building 9, D-66421 Homburg, Germany, Germany,
(2) Fertility Center Dr. Sebastian Grewe and Dr. Olaf Drost - Bremer Zentrum für Fortpflanzungsmedizin (BZF), Bremen, Germany, Germany,
(3) Schleswig-Holstein University Medical Center, Lübeck, Germany, Germany

Abstract

N/A

Full text article

Generated from XML file

References

Weiss T. Ökonomische Bestimmungsgrößen der Fertilität in westlichen Industrieländern. Bundesinstitut für Bevölkerungsforschung; 1996

Menken J, Trussell J, Larsen U. Age and infertility. Science 1986; 233:1389-1394

Mattle V, Behringer K, Engert A, Wildt L. Female fertility after cytotoxic therapy-protection of ovarian function during chemotherapy of malignant and non-malignant diseases. Eur J Haematol Suppl 2005;77-82

Anderson RA, Wallace WH, Baird DT. Ovarian cryopreservation for fertility preservation: indications and outcomes. Reproduction 2008;136:681-689

Lee MC et al. Fertility and reproductive considerations in premenopausal patients with breast cancer. Cancer Control 2010;17(3):162-172

Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pacific journal of cancer prevention (APJCP) 2016;17:43-46

Radecka B, Litwiniuk M. Breast cancer in young women. Ginekologia polska 2016;87:659-663

Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Annals of oncology : official journal of the European Society for Medical Oncology 1990;1:183-188

Sukumvanich P, Case LD, Van Zee K, Singletary SE, Paskett ED, Petrek JA et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer 2010;116:3102-3111

Kleinstein J. GnRH-Analoga und Add-back-Verfahren. J Gyn Endokrinol 2008;2(2):40-43

von Wolff M, Dian D. Fertility Preservation in Women With Malignant Tumors and Gonadotoxic Treatments. Dtsch Ärztebl Int 2012;109(12):220-226

Arbeitsgemeinschaft Gynäkologische Onkologie. Kommission Mamma. Diagnostik und Therapie früher und fortgeschrittener Mammakarzinome; 2020

Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertility and sterility 2013;100:1673-1680

von Wolff M, Capp E, Jauckus J, Strowitzki T, Germeyer A, Ferti Psg. Timing of ovarian stimulation in patients prior to gonadotoxic therapy: an analysis of 684 stimulations. Eur J Obstet Gynecol and Reprod Biol 2016;199:146-149

von Wolff M, Dittrich R, Liebenthron J, Nawroth F, Schuring AN, Bruckner T et al. 2015. Fertility-preservation counselling and treatment for medical reasons: data from a multinational network of over 5000 women. Reprod Biomed Online 2015;31:605-612

von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM et al. Ovarian stimulation to

cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertility and

steril 2009;92:1360-1365

Moffat R, Pirtea P, Gayet V, Wolf JP, Chapron C, de Ziegler D. Dual ovarian stimulation is a new viable option for enhancing the oocyte yield when the time for assisted reproductive technnology is limited. Reprod Biomed Online 2014;29:659-661

Turan V, Bedoschi G, Moy F, Oktay K. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil Steril 2013;100:1681-1685e1

Zhang J. Luteal phase ovarian stimulation following oocyte retrieval: is it helpful for poor responders? Reprod Bbiology Endocrinol 2015; 13:76

Lawrenz B, Jauckus J, Kupka M, Strowitzki T, von Wolff M. Efficacy and safety of ovarian stimulation before chemotherapy in 205 cases. Fertil Steril 2010;94:2871-2873

Diaz-Garcia C, Domingo J, Garcia-Velasco JA, Herraiz S, Mirabet V, Iniesta I et al. Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: a prospective cohort study. Fertil Steril 2018;109:478-485e2

Register DI. 2018. 16. Jahrgang 2019 // Modifizierter Nachdruck aus Nummer 6: 279–315 // ISSN 1810-2107. Journal of Reproductive Medicine and Endocrinology

Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer. Journal of Clinical Oncology 2015;33:2424-2429

Haas J, Bassil R, Meriano J, Samara N, Barzilay E, Gonen N et al. Does daily co-administration of letrozole and gonadotropins during ovarian stimulation improve IVF outcome? Reprod Biol Endocrinol 2017;15:70

Kim J, Turan V, Oktay K. Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer. The Journal of clinical endocrinology and metabolism 2016;101:1364-1371

Sharma S, Ghosh S, Singh S, Chakravarty A, Ganesh A, Rajani S et al. Congenital malformations among babies born following letrozole or clomiphene for infertility treatment. PloS one 2014;9:e108219

Findeklee S, Radosa JC, Takacs Z, Hamza A, Sima RM, Solomayer EF et al. Fertility preservation in female cancer patients: current knowledge and future perspectives. Minerva Ginecol 2019;71(4):298-305

Regan MM, Walley BA, Francis PA, Fleming GF, Láng I, Gómez HL et al. Concurrent and

sequential initiation of ovarian function suppression with chemotherapy in

premenopausal women with endocrine-responsive early breast cancer: an exploratory

analysis of TEXT and SOFT. Annals of oncology 2017;28:2225-2232

Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) DGfRD, Deutsche

Gesellschaft für Urologie (DGU). Leitlinie: Fertilitätserhaltung bei onkologischen

Therapien. Level S2k, AWMF Register Nr. 015/082;2017

Dolmans MM, Masciangelo R. Risk of transplanting malignant cells in cryopreserved

ovarian tissue. Minerva Ginecol 2018;70:436-443

Authors

Sebastian Findeklee
sebastian.findeklee@uks.eu (Primary Contact)
Sebastian Grewe
Klaus Diedrich
Author Biographies

Sebastian Grewe, Fertility Center Dr. Sebastian Grewe and Dr. Olaf Drost - Bremer Zentrum für Fortpflanzungsmedizin (BZF), Bremen, Germany

Dr. Grewe contributed to the article as co-author.

Klaus Diedrich, Schleswig-Holstein University Medical Center, Lübeck, Germany

Professor Diedrich contributed to the article as co-author.

1.
Findeklee S, Grewe S, Diedrich K. Fertility Preservation in Breast Cancer Patients Under Special Consideration of Ovarian Stimulation for Fertility Purposes. Arch Breast Cancer [Internet]. 2020 Nov. 16 [cited 2024 Jun. 16];:149-54. Available from: https://www.archbreastcancer.com/index.php/abc/article/view/330

Article Details